A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 794 participants.
Also called NCT05433584
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 794 participants
- Sponsor
- Registry
-
NCT05433584 -
2022-000130-42 -
U1111-1282-0263
-
- Other papers using this trial's data
- Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United States, Argentina, Canada, Germany, Israel, Italy, Mexico, Puerto Rico, Romania, Slovakia, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05433584. Randomized; no masking; primary purpose treatment. Start 2022-08-01 (actual); primary completion 2025-10-21 (actual). Results posted on 2026-11-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
- Acronym
- SURPASS-EARLY
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Antihyperglycemic medication
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05433584- Content hash
b99573e9257379e5bc4b1d3a1213205b2ba61b5a137de65fdf5a66927e13639e